VRX.TO - Valeant Pharmaceuticals International, Inc.

Toronto - Toronto Delayed Price. Currency in CAD
28.54
+0.49 (+1.75%)
At close: 4:19PM EDT
Stock chart is not supported by your current browser
Previous Close28.05
Open28.29
Bid28.40 x 0
Ask28.73 x 0
Day's Range28.29 - 28.69
52 Week Range14.01 - 30.56
Volume923,168
Avg. Volume1,218,050
Market Cap9.951B
Beta-2.02
PE Ratio (TTM)4.18
EPS (TTM)6.83
Earnings DateAug 7, 2018 - Aug 13, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend Date2010-11-10
1y Target Est19.41
  • Financial Times8 hours ago

    [$$] Leveraged loan rush sees borrowers gain balance of power

    was under investigation by the US Securities and Exchange Commission and investors were questioning its opaque accounting. Now, the company, which in July will rebrand itself as Bausch Health, is firmly in control of the refinancing of a loan. The reversal in the balance of power between the drugmaker and investors is a striking example of white-hot demand for leveraged loans, or those made to speculative grade-rated borrowers.

  • Benzinga3 days ago

    Cantor Fitzgerald: 18 Drug Companies With Catalysts Worth Watching

    The biotech analysts at Cantor Fitzgerald have a packed calendar: here are some of the dates they’re tracking and why they’re important. Mallinckrodt PLC (NYSE: MNK ) is expected to release Phase 4 interim ...

  • PR Newswire5 days ago

    Valeant Announces Pricing Of Private Offering Of Notes

    LAVAL, Quebec, May 17, 2018 /PRNewswire/ -- Valeant Pharmaceuticals International, Inc. (NYSE/TSX: VRX) ("Valeant" or the "Company") today announced that Valeant Pharmaceuticals International (the "Issuer"), the Company's wholly owned indirect subsidiary, has priced its previously announced offering of $750,000,000 aggregate principal amount of 8.50% unsecured senior notes due 2027 (the "Notes"). As previously announced, the Company is seeking to amend and restate its existing credit agreement (as amended and restated, the "New Credit Agreement") and borrow $4.565 billion of new Term B loans (the "New Term B Loans") under the New Credit Agreement (the "Refinancing"). The proceeds of the Notes and the New Term B Loans, along with cash on hand, are expected to be used to refinance the Company's outstanding Term B loans and redeem the Company's 5.375% Senior Notes due 2020, the Issuer's 6.375% Senior Notes due 2020, the Issuer's 6.75% Senior Notes due 2021 and the Issuer's 7.25% Senior Notes due 2022, and to pay related fees and expenses.

  • MarketWatch5 days ago

    Valeant launches $750 million bond offering, increases planned Term B loan borrowing

    Valeant Pharmaceuticals International Inc. said Thursday it has launched a $750 million offering of senior unsecured notes due 2027 and increased the size of planned term loan borrowings. The company said ...

  • PR Newswire5 days ago

    Valeant Announces Launch Of Private Offering Of Notes And Upsize Of Term Loans

    LAVAL, Quebec, May 17, 2018 /PRNewswire/ -- Valeant Pharmaceuticals International, Inc. (NYSE/TSX: VRX) ("Valeant" or the "Company") today announced that Valeant Pharmaceuticals International (the "Issuer"), the Company's wholly owned indirect subsidiary, has launched an offering of $750,000,000 aggregate principal amount of unsecured senior notes due 2027 (the "Notes"). As previously announced, the Company is seeking to amend and restate its existing credit agreement (as amended and restated, the "New Credit Agreement") and borrow $4.565 billion of new Term B loans (the "New Term B Loans") under the New Credit Agreement (the "Refinancing"), which reflects an increase from the previously announced $3.815 billion of New Term B Loans. The proceeds of the Notes and the New Term B Loans, along with cash on hand, are expected to be used to refinance the Company's outstanding Term B loans and redeem the Company's 5.375% Senior Notes due 2020, the Issuer's 6.375% Senior Notes due 2020, the Issuer's 6.75% Senior Notes due 2021 and the Issuer's 7.25% Senior Notes due 2022, and to pay related fees and expenses.

  • Bloomberg7 days ago

    Valeant Ex-CEO Wasn't Swayed by Philidor Warning, Witness Says

    Valeant Pharmaceuticals International Inc.’s former leadership approved a $133 million investment in a mail-order pharmacy in 2014 even after being warned of a potentially corrupt relationship at the heart of the deal, an ex-official at the drug manufacturer testified. The option-purchase agreement with Philidor Rx Services LLC is at the center of the government’s fraud and money-laundering trial of former Valeant executive Gary Tanner and ex-Philidor Chief Executive Officer Andrew Davenport. Tanner, who managed Valeant’s relationship with Philidor, allegedly manipulated his employer into the deal in exchange for a $9.7 million kickback.

  • Barrons.com7 days ago

    Valeant: Turning Around or Just Spinning?

    Valeant Pharmaceuticals International (VRX) is higher today, helped by an upgrade from Mizuho Securities. Analyst Irina Koffler upgraded the shares to Buy from Neutral and raised her price target to $27 from $15, writing that the move comes after a drug-by-drug review that shows the company is "growing its key brands and has stabilized losses from older products," and there is also potential for upside from its pipeline. Koffler writes that Valeant's portfolio now looks "Mylan (MYL)-like," i.e.

  • The Wall Street Journal7 days ago

    Stocks to Watch: Home Depot, Amazon, Symantec, Wynn, CBS, Viacom, Tesla, Ford, Micron, Valeant

    Among the companies with shares expected to trade actively in Tuesday's session are Home Depot, Amazon.com, Symantec, Wynn Resorts and CBS.

  • PR Newswire7 days ago

    Valeant to Participate at the 2018 Barclays High Yield Bond and Syndicated Loan Conference

    LAVAL, Quebec , May 15, 2018 /PRNewswire/ -- Valeant Pharmaceuticals International, Inc. (NYSE/TSX: VRX) ("Valeant") today announced that Paul S. Herendeen , executive vice president, Finance ...

  • Bill Ackman’s Big Deals Don’t Look Better in Hindsight
    Bloomberg7 days ago

    Bill Ackman’s Big Deals Don’t Look Better in Hindsight

    A new book portrays an activist investor who let his ego get in the way of good judgment.

  • Ex-Valeant Official Says He Suspected Secret Financial Stake
    Bloomberg8 days ago

    Ex-Valeant Official Says He Suspected Secret Financial Stake

    A former Valeant Pharmaceuticals International Inc. executive told a jury how he became concerned that one of his senior directors had a secret financial interest in a mail-order pharmacy that did business with the drug company. Laizer Kornwasser, one the government’s star witnesses in the fraud and money-laundering trial of Gary Tanner and Andrew Davenport, the former head of Philidor Rx Services LLC, took the witness stand Monday in Manhattan federal court.

  • Thomson Reuters StreetEvents8 days ago

    Edited Transcript of VRX.TO earnings conference call or presentation 8-May-18 12:00pm GMT

    Q1 2018 Valeant Pharmaceuticals International Inc Earnings Call

  • Benzinga9 days ago

    Barron's Picks And Pans: Arista, Kroger, SeaWorld, Valeant And More

    This weekend's Barron's cover story looks at why the buyback boom is bullish for investors. "Why the Buyback Boom Is Bullish for Investors" by Andrew Bary suggests that big corporations such as Apple Inc. (NASDAQ: AAPL) and JPMorgan Chase & Co. (NYSE: JPM) have gone on a spending spree, repurchasing their shares in record amounts. Will others, such as Alphabet Inc (NASDAQ: GOOGL), follow suit?

  • Valeant (VRX) Rallies on Earnings Beat in Q1, Raises View
    Zacks12 days ago

    Valeant (VRX) Rallies on Earnings Beat in Q1, Raises View

    Valeant's (VRX) first-quarter earnings topped estimates driven by growth in Bausch + Lomb/International segment and Salix businesses. The company also upped its view.

  • Reuters12 days ago

    In Europe, Mylan's rivals try to plug EpiPen shortages

    European makers of emergency allergy treatments are stepping up production of alternative life-saving adrenaline shots to try to fill intermittent shortages of Mylan's (MYL.O) market-leading EpiPen injection. Mylan began warning about EpiPen supply constraints in Britain two months ago. Canada has also seen similar problems, while on Wednesday the Food and Drug Administration added EpiPens to its list of drugs in shortage in the United States.

  • PR Newswire12 days ago

    Valeant To Participate At 2018 Bank Of America Merrill Lynch Healthcare Conference

    LAVAL, Quebec , May 10, 2018 /PRNewswire/ -- Valeant Pharmaceuticals International, Inc. (NYSE/TSX: VRX) ("Valeant") today announced that Joseph C. Papa , chairman and chief executive officer, ...

  • MarketWatch12 days ago

    Valeant will borrow more than $3.82 bln

    Valeant Pharmaceuticals International Inc. said early Thursday that it plans to borrow an additional $3.815 billion of Term B loans and issue $750 million of secured debt securities and $750 million of unsecured debt securities. The move is expected to extend the maturity date of up to $1.2 billion to five years from the closing date, replace currently outstanding Term B loans with new ones that will mature seven years from the closing date and lower interest rates. Valeant will use proceeds from the new loans and debt securities to refinance outstanding Term B loans and redeem sets of senior notes due in 202, 2021 and 2022.

  • PR Newswire12 days ago

    Valeant To Seek Refinancing of its Existing Credit Agreement

    LAVAL, Quebec, May 10, 2018 /PRNewswire/ -- Valeant Pharmaceuticals International, Inc. (NYSE/TSX: VRX) ("Valeant" or the "Company") today announced that it is seeking to amend and restate its existing credit agreement (the "Credit Agreement") and borrow $3.815 billion of new Term B loans (the "New Term B Loans") under the Credit Agreement. The amendment and restatement is expected to have the effect of (i) extending the maturity date of the revolving facility to five years from the closing date, in an amount up to $1.2 billion (subject to a springing maturity with respect to the earlier maturity of debt in excess of $1.0 billion), (ii) replacing the Term B loans currently outstanding under the Credit Agreement with the New Term B Loans, which will have a maturity date that is seven years from the closing date, (iii) modifying the covenants to provide the Company with enhanced operating flexibility, (iv) adding the Company's wholly owned subsidiary, Valeant Pharmaceuticals International ("VPI") as a co-borrower and (v) lowering the interest rates applicable to the Credit Agreement.

  • Barrons.com13 days ago

    Valeant Earnings: One Day Later, Shares Are Still Rising

    Shares of Valeant Pharmaceuticals International (VRX) jumped on Tuesday, following its beat-and-raise first quarter and news that it will change the corporate name to Bausch Health Cos. in July (even if that didn't do much to lift the rest of the sector).  The stock is rising again today, and while at least one analyst sees Valeant pulling off "a turnaround for the ages," others are also positive, if not quite as enthusiastic. Valeant is up 1% to $19.96 in recent trading. The SPDR S&P Pharmaceuticals ETF (XPH) is up 1.5% to $39.75 this afternoon, and the Health Care Select Sector SPDR ETF (XLV) is 0.5% higher to $80.68.

  • 13 days ago

    Jim Cramer on Bausch Health: This Stock Is a Buy

    Valeant Pharmaceuticals is changing its name to Bausch Health and the stock is a buy, according to TheStreet's founder and Action Alerts PLUS Portfolio Manager Jim Cramer.

  • Valeant Pharmaceuticals (VRX) Catches Eye: Stock Jumps 8.9%
    Zacks13 days ago

    Valeant Pharmaceuticals (VRX) Catches Eye: Stock Jumps 8.9%

    Valeant Pharmaceuticals (VRX) saw a big move last session, as its shares jumped nearly 9% on the day, amid huge volumes.

  • See what the IHS Markit Score report has to say about Valeant Pharmaceuticals International Inc.
    Markit13 days ago

    See what the IHS Markit Score report has to say about Valeant Pharmaceuticals International Inc.

    The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Index (PMI) data, output in the Healthcare sector is rising.

  • MarketWatch13 days ago

    Valeant will get a new name to shed its scandals, but will it work?

    Valeant Pharmaceuticals International Inc. is hoping that a new name will put a rocky few years and an accounting scandal behind it — again. The change, to Bausch Health Companies Inc. and the new ticker BHC, is scheduled for July. It will be the company’s second scandal-inspired name change in less than 10 years.

  • CNBC13 days ago

    Cramer Remix: GE just got a huge break—the stock may have bottomed

    "Mad Money" host Jim Cramer thinks General Electric's worst days could be behind it thanks to the recent increase in oil prices. Cramer sits down with the CEOs of Valeant Pharmaceuticals and Broadridge Financial Solutions. Oil prices may have slid from their near-$70 highs after the United States withdrew from the Iran nuclear deal , but CNBC's Jim Cramer found an under-the-radar beneficiary of higher crude costs.

  • Valeant Pharma CEO: Seeing organic growth for first time ...
    CNBC Videos13 days ago

    Valeant Pharma CEO: Seeing organic growth for first time ...

    Jim Cramer sits down with Joseph Papa, the Chairman and CEO of Valeant Pharmaceuticals, after earnings to hear about his company's new products.